An International Multicentre, Phase 2, Randomised, Adaptive Protocol to determine the need for, optimal timing of and immunogenicity of administering a booster mRNA vaccination dose against SARS-CoV-2 in the general population (18+ years) already vaccinated against SARS-CoV-2 (EU-COVAT-2 BOOSTAVAC)
Latest Information Update: 21 Sep 2024
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms EU-COVAT-2 BOOSTAVAC
Most Recent Events
- 14 Jun 2024 This trial has been completed in Ireland according to European Clinical Trials Database record.
- 13 Jun 2024 This trial has been completed in Germany according to European Clinical Trials Database record.
- 14 Jan 2022 New trial record